ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0776

Genetics of Neonatal Lupus Erythematosus Risk and Specific Manifestations

Melissa Misztal1, Fangming Liao2, Talia Diaz2, Zeynep Baskurt2, JingJing Cao2, Daniela Dominguez2, Deborah Levy2, Andrea Knight3 and Linda Hiraki2, 1The Hospital for Sick Children, Oakville, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Hospital for Sick Children, Toronto, ON, Canada

Meeting: ACR Convergence 2021

Keywords: Congenital Heart Block, genetics, Neonatal Lupus Erythematosus

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Neonatal lupus erythematosus (NLE) is a passively acquired autoimmune disease in infants, secondary to the transplacental passage of maternal autoantibodies against Ro and/or La. The presence of anti-Ro and/or La antibodies are necessary for NLE, but insufficient for disease suggesting additional risk factors. Genetics may impact NLE risk. We analyzed systemic lupus erythematosus (SLE) susceptibility loci in infants and their anti-Ro antibody positive mothers, with NLE risk and NLE specific manifestations.

Methods: We recruited infants born to anti-Ro positive mothers from the NLE clinic at The Hospital for Sick Children. Infants and mothers underwent genotyping on the Illumina Global Screening Array. Ancestry was genetically inferred from principal components (PCs) and Admixture, or self-reported based on Canada census categories. We created additive non-HLA SLE polygenic risk scores (PRSs) using 70 common SLE-risk SNPs from the largest SLE genome wide association study to date. Outcomes were defined as (1) any NLE, (2) cardiac NLE and (3) cutaneous NLE. We tested the association between SLE PRSs in the infant and in the mother with NLE outcomes, in logistic regression models using Generalized linear Mixed Model Association Tests (GMMAT). GMMAT enables inclusion of first-degree relatives in analyses by accounting for relatedness. In order to examine the degree of discordance between maternal and infant PRS, we regressed the difference between mother and infant PRS on NLE outcomes. Models were adjusted for PCs, prior NLE affected infants, maternal rheumatic disease status and hydroxychloroquine use during pregnancy.

Results: The study included 287 infants born to 233 anti-Ro positive mothers, with 212 genotyped maternal-infant pairs. The majority of infants were European (41%) or East Asian (18%), 52% were female, and 8% had a prior NLE affected sibling. Over half of the infants in the cohort had NLE (54%), including 7% with cardiac NLE and 13% with cutaneous NLE. Of the mothers, 41% were European and 21% were East Asian. A total of 168 mothers (72%) had a rheumatic disease diagnosis and 90 mothers (39%) were on hydroxychloroquine during pregnancy (Table 1).

We did not observe a significant association between infant, maternal or maternal-infant SLE-PRSs and any NLE, cardiac NLE or cutaneous NLE in adjusted GMMAT models (Table 2).

Conclusion: In our multiethnic cohort of infants born to Ro positive mothers, we did not identify a significant association between SLE genetics and risk of NLE or its manifestations. Additional studies are required to replicate our findings.

Table 1. Cohort Demographics and NLE Manifestations.
a Data includes 21 infants with self-reported ethnicity instead of genetically inferred ancestry, and 2 infants without genetically inferred or self-reported ethnicity.
b Percentage of total cardiac NLE cases.
c Percentage of total hematologic NLE cases.
d Percentage of total rheumatic disease diagnoses.

Table 2. Association between SLE-PRS and NLE Outcome. a
a Models adjusted for PCs, prior NLE affected infants, maternal rheumatic disease and maternal hydroxychloroquine use during pregnancy.


Disclosures: M. Misztal, None; F. Liao, None; T. Diaz, None; Z. Baskurt, None; J. Cao, None; D. Dominguez, None; D. Levy, amgen, 6, sobi, 1, roche, 1, janssen, 1, medexus, 6; A. Knight, None; L. Hiraki, Novartis, 6.

To cite this abstract in AMA style:

Misztal M, Liao F, Diaz T, Baskurt Z, Cao J, Dominguez D, Levy D, Knight A, Hiraki L. Genetics of Neonatal Lupus Erythematosus Risk and Specific Manifestations [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/genetics-of-neonatal-lupus-erythematosus-risk-and-specific-manifestations/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetics-of-neonatal-lupus-erythematosus-risk-and-specific-manifestations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences